Collectively, these mechanisms converge to sustain aberrant PI3K/AKT/mTOR activation, leading to excessive megakaryopoiesis and pathological thrombocytosis in patients carrying such mutations. This evidence concerns the gene AKT1 and thrombocytosis disease.